Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: Vasculotide, an Angiopoietin-1 mimetic, ameliorates several features of experimental atopic dermatitis-like disease

Fig. 1

Depiction of the transgenes used in this study and the AT-Derm phenotype. a Diagram of the engineered transgenes. The animals expressing pTek-tTA and pTetos-Tie2 together develop the AT-Derm phenotype as seen in 7 day old mice (right) compared to a wildtype littermate (left). The scaly skin phenotype of the AT-Derm animal is clearly evident. The Ang1 and Ang2 responder transgenes are also depicted to the right. b Gross phenotypic improvement is noted when experimental AT-Derm mice are crossed to the Ang1 pTetOS-Ang1 mice, triple transgenic (pTek-tTA: pTetOS-Tie2: pTetOS-Ang1). Superficially, these effects are seen by a decrease in erythema around the nose and eyes. Also noted is a reduction in ear micro haemorrhages and tail scaly plaque formation (not shown). c AT-Derm Ang2-expressing triple transgenic mice present with increased erythema, micro haemorrhages and tail plaque (not shown). d Wild type and the Ang2-double transgenic (pTek-tTA: pTetOS-Ang2) exhibit no phenotype, whereas, the AT-Derm present with the characteristic erythema around the nose and eyes, which is much more accentuated in the AT-Derm+Ang2 triple transgenics. e Same animals as in panel d viewed from above, further illustrating the increased micro-hemorrhages in the ears

Back to article page
\